In this study, a simple, specific, and isocratic reversed phase-high performance liquid chromatography (RP-HPLC) method was successfully developed and validated for the analysis of moxifloxacin hydrochloride (MOXI) in the presence of its degradation products. The Agela Technology Venosil XBP C18 column, with dimensions 4.6mm×250mm and particle size of 10μm, was employed for chromatographic separation, resulting in a sharp and well-defined moxifloxacin peak at a retention time of 9.99 minutes. The optimized mobile phase composition of phosphate buffer and methanol (18:7 v/v) at a flow rate of 1.3 mL/min, coupled with a column oven maintained at 50°C, provided efficient and reproducible separation throughout the study. The use of 0.1N HCl as the diluent further supported the sensitivity and specificity of the method. The calibration curve demonstrated excellent linearity, with a correlation coefficient (R 2 ) of 0.999, meeting the criteria outlined by the ICH guidelines. The and quantification limit were found as 0.029 µg mL -1 and 0.095 µg mL -1 respectively. The developed RP-HPLC method with UV detection at 293 nm showcased its sensitivity and specificity in successfully quantifying moxifloxacin in pharmaceutical formulations, even in the presence of potential degradation products. The diluent used in the analytical method of moxifloxacin determination is very low cost and easily available that will provide provision for low-cost medicine. Overall, the results indicate that the proposed method holds promise for routine analysis in pharmaceutical quality control laboratories, providing a valuable tool for accurate and efficient moxifloxacin quantification.